Our Cancer Program Clinical Trials Currently Ongoing

White Plains Hospital offers several clinical trials, listed below, offering hope for patients who may not respond to established protocols. For more information, contact Marisa Cortese, Ph.D at 914-849-7582 or email clinicaltrials@wphospital.org.

Bladder

NRG-GU001: Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy For pT3/pT4 Urothelial Bladder Cancer (J. Vainshtein)

Breast

A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (C. Greenstein)

A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study (ALTERNATE) (S. Sadan)

A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (R. Stevens)

A011502: A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (R. Stevens)

E1Z11: A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (K.Green)

E2112: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer (K. Green)

NRG-BR002: Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (J. Vainshtein)

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (K. Green)

NSABP-B55: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (D. Costin)

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer (K.Green)

S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer (K. Green)

S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy (D. Costin)

Concordance / Basic Research

Foundation Medicine ctDNA: Study of Concordance Between Circulating Tumor DNA Assay and Foundation One Tissue Analysis For Genomic Alterations (D. Costin)

Gynecologic

GOG-0281: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer (D. Costin)

NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer (D. Costin)

NRG-GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or –refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) (D. Costin)

Head & Neck

NRG-HN002: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer (J. Vainshtein)

Liver

MK-3475-KN240: A Phase III Study of Pemobrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE 240) (D. Costin)

Lung

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (J. Raff)

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (J. Raff)

CA209-370 CHECKMATE: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies (D. Costin)

E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (J. Raff)

EA5142: A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ANVIL) (J. Raff)

IELCAP: White Plains Hospital Lung Cancer Screening Program (C. Chin)

Lung Biopsy: Next Generation DNA Sequencing of Malignant Tumors Obtained by Lung Biopsy: A Prospective Clinical Registry (D. Costin)

Melanoma

E3612: A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma (D. Costin)

Multiple Myeloma

E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (J. Raff)

Newly Diagnosed / Quality of Life

DEALS-EPS: Dietary Education and Livestrong Exercise Program Study (D. Costin)

Pancreatic

PCEDP: Early Detection for Pancreatic Adenocarcinoma in Patients at Elevated Risk (J. Raff)

Prostate

PCORI: Development of Practice Outcome Measures to Account for Individual Differences and Temporal Changes in Quality of Life Appraisal (S. Lerner)

S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (D. Costin)

Sarcoma

A091304: A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma (D. Costin)

Solid Tumors and Lymphomas

EAY131: Molecular Analysis for Therapy Choice (MATCH) (J. Monroe)

Supportive Care

Rocktape: A Randomized Placebo Control Trial for Pain Management in Cancer Patients Using Best Supportive Care for Pain Management With or Without Rocktape (D. Costin)

Tommie Copper: Pilot Evaluation of Tommie Copper Material and Its Impact on Pain Control (D. Costin)

To learn more call 914-849-7582